TY - JOUR
T1 - The unmet need in rheumatology
T2 - Reports from the targeted therapies meeting 2017
AU - Winthrop, Kevin L.
AU - Strand, Vibeke
AU - van der Heijde, Désirée
AU - Mease, Philip
AU - Crow, Mary
AU - Weinblatt, Michael
AU - Bathon, Joan
AU - Burmester, Gerd R.
AU - Dougados, Maxime
AU - Kay, Johnathan
AU - Mariette, Xavier
AU - Van Vollenhoven, Ronald
AU - Sieper, Joachim
AU - Melchers, Fritz
AU - Breedfeld, Ferdinand C.
AU - Kalden, Joachim
AU - Smolen, Josef S.
AU - Furst, Daniel E.
N1 - Publisher Copyright:
© 2017 Elsevier Inc.
PY - 2018/1
Y1 - 2018/1
N2 - The 19th annual international Targeted Therapies meeting brought together over 100 leading basic scientists and clinical researchers from around the world in the field of immunology, molecular biology and rheumatology and other specialties. During the meeting, breakout sessions were held consisting of 5 disease-specific groups with 20–40 experts assigned to each group based on clinical or scientific expertise. Specific groups included: rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, systemic lupus erythematous, connective tissue diseases (e.g. Sjogren's syndrome, Systemic sclerosis, vasculitis including Bechet's and IgG4 related disease), and a basic science immunology group spanning all of the above clinical domains. In each group, experts were asked to consider and update previously identified unmet needs in 3 categorical areas: basic/translational science, clinical science and therapeutic development, and clinical care. Overall, similar primary unmet needs were identified within each disease foci, and several additional needs were identified since the time of last year's congress. Within translational/basic science, the need for better understanding the heterogeneity within each disease was highlighted so that predictive tools for therapeutic responses can be developed. Within clinical science and therapeutic trials, a strong focus was placed upon the need to identify pre-clinical states of disease allowing prevention in those at risk. The ability to cure remains perhaps the ultimate unmet need. Further, the need to develop new and affordable therapeutics, as well as to conduct strategic trials of currently approved therapies was again highlighted. Within the clinical care realm, improved co-morbidity management and patient-centered care were identified as unmet needs. Lastly, it was strongly felt there was a need to develop a scientific infrastructure for well-characterized, longitudinal cohorts paired with biobanks and mechanisms to support data-sharing. This infrastructure could facilitate many of the unmet needs identified within each disease area.
AB - The 19th annual international Targeted Therapies meeting brought together over 100 leading basic scientists and clinical researchers from around the world in the field of immunology, molecular biology and rheumatology and other specialties. During the meeting, breakout sessions were held consisting of 5 disease-specific groups with 20–40 experts assigned to each group based on clinical or scientific expertise. Specific groups included: rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, systemic lupus erythematous, connective tissue diseases (e.g. Sjogren's syndrome, Systemic sclerosis, vasculitis including Bechet's and IgG4 related disease), and a basic science immunology group spanning all of the above clinical domains. In each group, experts were asked to consider and update previously identified unmet needs in 3 categorical areas: basic/translational science, clinical science and therapeutic development, and clinical care. Overall, similar primary unmet needs were identified within each disease foci, and several additional needs were identified since the time of last year's congress. Within translational/basic science, the need for better understanding the heterogeneity within each disease was highlighted so that predictive tools for therapeutic responses can be developed. Within clinical science and therapeutic trials, a strong focus was placed upon the need to identify pre-clinical states of disease allowing prevention in those at risk. The ability to cure remains perhaps the ultimate unmet need. Further, the need to develop new and affordable therapeutics, as well as to conduct strategic trials of currently approved therapies was again highlighted. Within the clinical care realm, improved co-morbidity management and patient-centered care were identified as unmet needs. Lastly, it was strongly felt there was a need to develop a scientific infrastructure for well-characterized, longitudinal cohorts paired with biobanks and mechanisms to support data-sharing. This infrastructure could facilitate many of the unmet needs identified within each disease area.
KW - Ankylosing spondylitis
KW - Inflammatory myopathies
KW - Psoriatic arthritis
KW - Rheumatoid arthritis
KW - Sjögren's syndrome
KW - Spondyloarthritis
KW - Systemic lupus erythematosus
KW - Systemic sclerosis
KW - Vasculitis
UR - http://www.scopus.com/inward/record.url?scp=85028377533&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85028377533&partnerID=8YFLogxK
U2 - 10.1016/j.clim.2017.08.009
DO - 10.1016/j.clim.2017.08.009
M3 - Article
C2 - 28811201
AN - SCOPUS:85028377533
SN - 1521-6616
VL - 186
SP - 87
EP - 93
JO - Clinical Immunology
JF - Clinical Immunology
ER -